Sign in
Taking people in United StatesNo phase

Shockwave therapy for knee osteoarthritis after an ACL injury

Tests shockwave therapy for knee osteoarthritis in athletes after ACL surgery.

Key facts

Who runs it
Spaulding Rehabilitation Hospital
Where
Cambridge, United StatesSee the site
Trial code
Registry title
Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy
Status
Recruiting
People taking part
70 people, planned
Started
1 Apr 2025
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • extracorporeal shockwave therapy (ESWT)
  • Sham Comparator
Record updated
25 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for current or former athletes with knee osteoarthritis (joint wear) after ACL reconstruction surgery on one knee. It tests shockwave therapy (ESWT) against a fake (sham) treatment.

Age
18 to 55 years
Sex
All sexes
Disease stage
Knee osteoarthritis after injury (PTOA), diagnosed by a medical professional and confirmed on X-ray. Knee pain is the main pain. A score of 85 or lower on 2 of 4 KOOS areas (pain, symptoms, daily activities, quality of life).
Earlier treatment
ACL reconstruction with an autograft or allograft at least one year ago. Cannot join after knee joint injections in the past 3 months, earlier ESWT for knee osteoarthritis with the study devices, or ACL revision surgery.

Main reasons for not taking part

  • Pregnant or planning to become pregnant
  • ACL injury or surgery in both knees
  • Nerve damage (neuropathy) affecting pain, or heart disease that shockwave therapy could affect
  • Chronic rheumatic, immune or connective tissue disease, active cancer, or current oral steroids or anti-inflammatories
  • Pacemaker, bone screws or other metal implants that prevent MRI or ESWT; not speaking English

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Previous ACL reconstruction using an autograft or allograft in the knee with PTOA
  • Minimum of one year following ACL reconstruction surgery
  • Between ages of 18 and 55
  • No clear contraindication to complete protocol including mechanical symptoms which would limit ability to complete the study
  • Score on KOOS for 2 of 4 domains (pain, symptoms, activities of daily living (ADL), quality of life (QOL)) of 85 or lower
  • Primary pain is coming from the knee
  • Diagnosis of PTOA based on clinical diagnosis and confirmation with radiographic evidence by a medical professional prior to study enrollment. If individuals have suspected OA based on impairments such as pain, they must have a score on KOOS for 2 of 4 domains (pain, symptoms, activities of daily living (ADL), quality of life (QOL)) of 85 or lower to participate in the study

Who cannot take part

  • Have previously received injections to the knee joint within the past 3 months
  • No active use of oral steroids or anti-inflammatories at the time of enrollment
  • Have bilateral ACL injury or reconstruction surgery, or have had ACL revision surgery
  • Previous ESWT treatment using study treatment devices for management of knee osteoarthritis
  • Have a pacemaker, bone screws, or any other metal implants that would prohibit participation in an MRI scan or EWST
  • Participants with a known underlying cardiac disease that could be affected by shockwave therapy
  • Chronic rheumatological conditions, immunodeficiency, severe asthma, connective tissue disorder (i.e. Ehlers-Danlos Syndrome), or other medical conditions (ex. active malignancy, severe asthma) outside of PTOA that are known to impact inflammatory state or requiring chronic use of oral or intravenous immune modulatory medications. Asthma requiring use of inhalers only is not an exclusion criteria
  • No active malignancy and at least five years in remission
  • Women who are pregnant or those who are planning to become pregnant. This is due to the fact that pregnancy will reduce participants activity after the treatment and the safety concerns related to shockwave treatment. - Participants with neuropathy affecting sensation to pain
  • Neuropathy diagnosis that can affect response to pain
  • Non-English speaking individuals

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • Spaulding Cambridge HospitalCambridge, United StatesContact: Michelle Bruneau, PhD,DPTTaking people

About the trial

What the trial wants to find out

This study is recruiting current or former athletes who had ACL reconstruction surgery over a year ago and have been diagnosed with knee osteoarthritis (OA). We are doing the research to investigate the effects of extracorporeal shockwave therapy (ESWT) on pain, function, biomechanics, knee range of motion and strength, inflammation, and joint structure and integrity of the knee.

The 2 groups in the trial

  • Control Group: Sham ESWT ArmSham treatment, for comparison

    All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 days to account for ongoing challenges for respiratory illness and scheduling/traveling conflicts. After collecting baseline variables and after blood is drawn, they will receive sham ESWT administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.

    Treatment: Sham Comparator

  • Treatment Group: ESWT ArmTreatment being tested

    All participants will review the exercise program prior to randomization and receiving treatment. Participants in the ESWT group will receive ESWT. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Radial and focused shockwave will be delivered to the knee and lower leg landmarks. The energy settings that will be used are consistent with mild to moderate ESWT which are commonly used in clinical practice to treat knee OA. During the ESWT treatment, a curtain will obscure participants from viewing their leg to blind them from treatment they are receiving. Standard protocol for the ESWT procedure will be followed, including safety assessment and monitoring. Additionally, the patient will be prescribed a post-ESWT exercise protocol that is part of the standard of care, which will be reviewed prior to first treatment and before treatment allocation is decided to minimize risk of bias.

    Treatment: extracorporeal shockwave therapy (ESWT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy
Plain-language title
Shockwave therapy for knee osteoarthritis after an ACL injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06686680, who can take part
Record updated
25 September 2026